September 3, 2020

Listing Department   **Code: *532 321***
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Listing Department   **Code: *CADILAHC***
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Re.:   Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated September 3, 2020 titled "Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**

DHAVAL   Digitally signed by
NARENDRA   DHAVAL NARENDRA
                 SONI
SONI   Date: 2020.09.03
                 10:52:21 +05'30'

DHAVAL N. SONI
COMPANY SECRETARY

Encl.:   As above

Zydus Cadila receives final approval from the USFDA to market Midodrine Hydrochloride Tablets

Ahmedabad, September 3, 2020

Zydus Cadila received final approval from the USFDA to market Midodrine Hydrochloride Tablets (US RLD- ProAmatine Tablets) in the strengths of 2.5 mg, 5 mg, and 10 mg.

The drug is used for certain patients who have symptoms of low blood pressure when standing. This condition is also known as orthostatic hypotension. The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad.

The group now has 298 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila
Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.

***